Medicare Part B Drug and Biological Competitive Acquisition Program and Supporting Regulations in 42 CFR Sections 414.906, 414.908, 414.910, 414.914, 414.916, and 414.917

ICR 200805-0938-004

OMB: 0938-0954

Federal Form Document

Forms and Documents
Document
Name
Status
Supporting Statement A
2008-04-25
ICR Details
0938-0954 200805-0938-004
Historical Active 200505-0938-006
HHS/CMS
Medicare Part B Drug and Biological Competitive Acquisition Program and Supporting Regulations in 42 CFR Sections 414.906, 414.908, 414.910, 414.914, 414.916, and 414.917
Revision of a currently approved collection   No
Regular
Approved without change 06/12/2008
Retrieve Notice of Action (NOA) 05/06/2008
  Inventory as of this Action Requested Previously Approved
06/30/2011 36 Months From Approved 07/31/2008
156,000 0 10
31,188 0 80
0 0 0

Section 303(d) of the MMA provides an alternative payment methodology for Part B covered drugs that are not paid on a cost or prospective payment basis. In particular, Section 303(d) of the MMA amends Title XVIII of the Social Security Act (the Act) by adding a new section 1847B, which establishes a competitive acquisition program for the acquisition of and payment for Part B covered drugs and biologicals furnished on or after January 1, 2006.

PL: Pub.L. 108 - 173 303(d)(1) Name of Law: Medicare Prescription Drug, Improvement, and Modernization Act of 2003
   PL: Pub.L. 109 - 432 108 Name of Law: MIEA-TRHCA 2006
   US Code: 42 USC 1395w-3b Name of Law: Competitive acquisition of outpatient drugs and biologicals
  
None

0938-AO65 Final or interim final rulemaking 72 FR 66260 11/27/2007

  73 FR 7560 02/08/2008
73 FR 22418 04/25/2008
No

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 156,000 10 0 155,990 0 0
Annual Time Burden (Hours) 31,188 80 0 31,108 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
Yes
Miscellaneous Actions
No
The MIEA-TRHCA of 2006 required the implementation of a post pay review process. Operationally, this translates to the requirement that CAP vendors submit drug administration verification information to CMS or its agent, though this information collection requirement is exempt from the PRA. Additionally, 42 CFR 414.906 allows a CAP vendor to voluntarily submit requests to add or substitute drugs onto their CAP drug list as needed. This was not reflected in the original PRA package and has now been added. It is also exempt from the PRA. 42 CFR 414.908 requires data to be submitted to facilitate programmatic operations. This was mentioned in the original PRA package, but the language has been updated. 414.917 was added to reflect language that requires information collection but is exempt from the PRA. Please see the supporting statement for additional information.

$0
No
No
Uncollected
Uncollected
Uncollected
Uncollected
Bonnie Harkless 4107865666

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
05/06/2008


© 2024 OMB.report | Privacy Policy